Atara Biotherapeutics vs HCW Biologics
Atara Biotherapeutics is the larger business, with $121m of revenue in fiscal 2025 against $54,232 for HCW Biologics (2227.0 times as much). Atara Biotherapeutics grew faster (-6.3% against -97.9%). Atara Biotherapeutics kept more of each dollar of sales as profit: a net margin of 27.1% against -14677.1%.
| Latest fiscal year | Atara BiotherapeuticsATRA, 2025 | HCW BiologicsHCWB, 2025 |
|---|---|---|
| Revenue | $121m | $54,232 |
| Revenue growth | -6.3% | -97.9% |
| Net income | $32.7m | −$8.0m |
| Operating margin | 29.7% | -24270.7% |
| Net margin | 27.1% | -14677.1% |
| Return on equity | — | — |
| Free cash flow | −$50.9m | −$13.4m |
| Cash | $8.5m | $2.0m |
| Total debt | $0 | $6.8m |
| Debt to equity | — | 246.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | 35 |
| Market value | $78.8m | $1.5m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 2 buys, 18 sales | 6 buys, 0 sales |